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HCC terminology needs to be standardized first. For 
example, what is an “incidental HCC”? Is this the same 
as a “small” HCC or an “asymptomatic HCC”? What 
tumor diameter should be used to define small HCC? 
Both 3 cm and 5 cm have been proposed. It was 
emphasized that not all HCCs are the same in biological 
behavior. They may vary depending on histological type 
(the fibrolamellar type is slower growing with a better 
prognosis), on cause (hepatitis B reactivation may occur 
in association with chemotherapy), on whether cirrhosis 
is present and perhaps on whether serum AFP values 
are elevated. In any trial these factors should be 
assessed, and perhaps patients enter into studies strat- 
ified according to some of these variables. Better means 
of assessing the response to therapy need to be used. One 
very promising approach is the use of a computer 
program, developed at Johns Hopkins Hospital, to 
measure tumor volume (10). 
In summary, therapies that may significantly benefit 
patients with HCC are being developed. Their worth will 
eventually need to be tested in controlled clinical trials 
requiring large numbers of patients. In the developed 
Western world, where HCC is relatively uncommon, 
such trials may need to be conducted in multiple centers 
using standardized terminology and methodology. 
ADRIAN M. DI BISCEGLIE, M.D. 
Liver Diseases Section 
National Institute of Diabetes and Digestive 
and Kidney Diseases 












Waterhouse J ,  Muir C, Correa P, Powell V, eds. Cancer incidence 
in five continents. Vol 111. Lyon, France: International Agency for 
Research on Cancer, World Health Organization, 1976. 
Kassianides CK, Kew MC. The clinical manifestations and natural 
history of hepatocellular carcinoma. Gastroenterol Clin North Am 
Lee C-S, Sung J-L, Hwang L-Y, Sheu JC, Chen DS, Lin TY, Beasley 
RP. Surgical treatment of 109 patients with symptomatic and 
asymptomatic hepatocellular carcinoma. Surgery 1986;99: 
Pichlmayr R. Is there a place for liver grafting for malignancy? 
Transplant Proc 1988;2O(suppl 1):478-482. 
Shen J-C, Sung J-L, Huang C-T, et al. Intra-tumor injection of 
absolute ethanol under ultrasound guidance for the treatment of 
small HCC. Hepatogastroenterology 1987;34:255-261. 
Lai C-L, Wu P-C, Chan GC-B, Lok ASF, Lin HJ. Doxorubicin 
versus no antitumor therapy in inoperable hepatocellular car- 
cinoma. Cancer 1988;62:479-483. 
Doci R, Bignami P, Bozzetti F, Bonfanti G, Anderson R, Colombo 
M, Gennari L. Intrahepatic chemotherapy for unresectable hepa- 
tocellular carcinoma. Cancer 1988;61: 1983- 1987. 
Order SE, Stillwagon GB, Klein JL, Leichner PK, Siegelman SS, 
Fishman EK, Ettinger DS, et al. Iodine 131 antiferritin, a new 
treatment modality in hepatoma: a radiation therapy oncology 
group study. J Clin Oncol 1985;3:1573-1582. 
Order S, Pajak T, Klein, et al. A randomized prospective 
trial in nonresectable hepatoma comparing Adriamycin and 
5-fluorouracil + 131-1 antiferritin: An RTOG study [Abstract]. 
Proc Am Soc Clin Oncol 1989;8:99. 
Kanematsu T, Furuta T, Takenaka K, Matsumata T, Yoshida Y, 
Nishizaki T, Hasuo K, et al. A 5-year experience of lipiodolization: 
selective regional chemotherapy for 200 patients with hepatocel- 
lular carcinoma. HEPATOLOGY 1989; 10:98- 102. 
1987;16:553-562. 
481-490. 
MORE ON GLUCOSE TRANSPORTERS: 
THE ACINAR ORGANIZATION FOR HEPATIC 
GLUCOSE TRANSPORT 
Tal M,  Schneider DL, Thorens B, Lodish HF. Restricted 
expression of the erythroidbrain glucose transporter 
isoform to perivenous hepatocytes in rats: modulation 
by glucose. J Clin Invest 1990;86:986-992. 
ABSTRACT 
The “erythroidhrain” glucose transporter (GT) 
isoform is expressed only in a subset of hepatocytes, 
those forming the first row around the terminal he- 
patic venules, while the “liver” GT is expressed in all 
hepatocytes. After 3 d of starvation, a three- to fourfold 
elevation of expression of the erythroidbrain GT 
mRNA and protein is detected in the liver as a whole; 
this correlates with the expression of this GT in more 
hepatocytes, those forming the first three to four rows 
around the hepatic venules. Starvation-dependent ex- 
pression of the erythroidfbrain GT on the plasma 
membrane of these additional hepatocytes is lost 
within 3 h of glucose refeeding; however, by immuno- 
blotting we show that the protein is still present. Its 
loss from the surface is possibly explained by internal- 
ization. 
COMMENTS 
Transport of glucose across the plasma membrane of 
mammalian cells can occur by a secondary active 
transport process such as in the small intestine or by 
facilitated diffusion. Facilitated diffusion of glucose is 
mediated by a family of related transport proteins 
having different tissue distribution and diverse regu- 
lation. To date, five functional facilitated diffusion 
transport systems and a pseudogene have been iden- 
tified (Table 1). These proteins vary in size from 492 
amino acids to 524 amino acids (1). Among the five 
functional forms a 39% to 65% identity and a 50% to 76% 
similarity exists. Twenty-six percent of the residues are 
identical in all five forms, whereas 13% are conservative 
substitutions (1). Two species of facilitated diffusion 
glucose transporters have been found in the liver, a less 
abundant erythroidbrain form or glut-1 and the main 
liver form or glut-2. These forms differ considerably in 
the Michaelis constant (K,) for glucose. Glut-1 has a K, 
of 1 to 2 mmol/L and thus is saturated at physiological 
concentrations of serum glucose (about 5 mmol/L). In 
contrast, glut-2 has a K, of 15 to 20 mmol/L. Therefore 
hepatic glucose homeostasis is subserved by the low- 
affinity liver isotype or glut-2. 
The two rat liver isoforms respond differently to 
conditions of fasting and refeeding and to experimental 
diabetes and insulin replacement. These different pat- 
terns of response led investigators to propose that these 
transporters are regulated by different mechanisms (2). 
In this paper, the authors, using polyclonal antibodies 
that specifically recognize either glut-1 or glut-2, immu- 
nolocalized the hepatocytes expressing these trans- 
porters. They observed that under control conditions, 
glut-2 was expressed in all hepatocytes. In contrast, 
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glut-1 was expressed only in one or two rows of 
hepatocytes surrounding the hepatic venule. Fasting for 
3 days resulted in an increment in the levels of glut-1 
apoprotein and messenger RNA (mRNA), whereas no 
major changes were observed in the levels of glut-2. 
Furthermore, the area of hepatocytes expressing glut-1 
expanded to about three to five rows of cells surrounding 
the hepatic venule. Glucose administration and re- 
feeding of the fasted rats resulted in a decrease in the 
number of hepatocytes expressing glut-1 to a control 
pattern. However, the concomitant administration of 
glucose and food in this study does not allow one to 
define the role of glucose in regulating the expression of 
glut-1 in acinar hepatocytes. 
Various aspects of this paper are of considerable 
interest. The restricted expression of glut-1 to a few 
hepatocytes surrounding the hepatic venule provides an 
explanation for previous observations by various groups 
(3,4) of low levels of expression of this transporter in the 
liver. In rat liver, mRNA levels of glut-1 represent about 
1% to 3% of the mRNA levels of the glut-2 transporter 
(2). The restricted expression of glut-1 also reinforces 
the proposal that the one to two rows of hepatocytes 
surrounding the hepatic venule represent a different 
state of differentiation of liver cells. It should be 
remembered that glutamine synthetase is also exclu- 
sively expressed in these hepatocytes (5 ) .  Therefore 
these genes may represent suitable models for the study 
of the regulation of hepatocyte-specific gene expression. 
Finally, the presence in all hepatocytes of glut-2 with a 
K, for glucose of 15 to 20 mmol/L points to a major role 
for this transporter in the bidirectional transport and 
regulation of glucose within the hepatic acinus. Fur- 
thermore, the location in the last two hepatocytes of a 
glucose transporter, glut-1, with a low K, for glucose, 
and thus functioning under conditions of saturation, 
suggests that the role of this transporter may not be the 
regulation of the levels of glucose reaching the systemic 
circulation. In contrast to glutamine synthetase, this 
transporter may not act in a scavenger role. Rather, the 
presence of this transporter at that location may indicate 
the need for glucose of those cells, suggesting that “the 
last hepatocyte” may survive in a very different meta- 
bolic state than more proximal hepatocytes. 
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POTENTIAL IMPORTANCE OF THE SEXUAL 
Alter MJ, Coleman PJ, Alexander WJ, Kramer E, Miller 
JK, Mandel E, Hadler SC, et al. Importance of hetero- 
sexual activity in the transmission of hepatitis B and 
non-A, non-B hepatitis. J A M A  1989;262: 1201-1205. 
TRANSMISSION OF NON-A, NON-B HEPATITIS 
ABSTRACT 
To identify previously unrecognized sources for 
acquiring acute hepatitis B and non-A, non-B (NANB) 
hepatitis, we interviewed patients with these types of 
